{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470476789
| IUPAC_name = (RS)-5-allyl-5-''sec''-butylpyrimidine-2,4,6(1''H'',3''H'',5''H'')-trione
| image = Talbutal.svg
| width = 120
<!--Clinical data-->
| tradename =  
| pregnancy_category = 
| legal_CA = Schedule IV
| legal_US = Schedule III
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 115-44-6
| ATC_prefix = N05
| ATC_suffix = CA07
| PubChem = 8275
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00306
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7976
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4YIR8202AX
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200802
<!--Chemical data-->
| C=11 | H=16 | N=2 | O=3
| molecular_weight = 224.256 g/mol
| smiles = O=C1NC(=O)NC(=O)C1(C(C)CC)C\C=C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BJVVMKUXKQHWJK-UHFFFAOYSA-N
| synonyms = <small>5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1''H'',3''H'',5''H'')-pyrimidinetrione</small>
}}

'''Talbutal''' ('''Lotusate''') is a [[barbiturate]] with a short to intermediate duration of action. It is a [[structural isomerism|structural isomer]] of [[butalbital]]. Talbutal is a schedule III drug in the U.S.

==Pharmacology==
Talbutal is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the [[central nervous system]] (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce [[anesthesia]].<ref name="Mutschler">{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=280ff|isbn=3-8047-1763-2}}</ref>

==Mechanism of action==
Talbutal binds at a distinct binding site associated with a Cl<sup>−</sup> ionopore at the [[GABAA receptor|GABA<sub>A</sub> receptor]], increasing the duration of time for which the Cl<sup>−</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

==Toxicity==
Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, [[hypotension]],<ref name="Mutschler" /> and shock.

==References==
{{Refimprove|date=December 2009}}
{{reflist}}


{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Barbiturates]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Allyl compounds]]


{{sedative-stub}}